A non-invasive measure of NRF2 activation may therefore provide an attractive solution for the prediction of therapy resistance in NSCLC, which may further reveal cancer-specific vulnerabilities for the precision treatment of refractive disease. The gene discussed is NFE2L2; the disease is cancer.